Prevalence of Human Papillomavirus Among Females After Vaccine Introduction—National Health and Nutrition Examination Survey, United States, 2003–2014

Within 8 years of vaccine introduction, 4vHPV-type prevalence decreased 71% among 14- to 19-year-olds and 61% among 20- to 24-year-olds. Estimated vaccine effectiveness was high. The decrease in 4vHPV-type prevalence among unvaccinated females suggests herd protection.